Conservative commentator Charlie Kirk shot and killed at Utah event
Director James Michael C. of Guided Therapeutics Inc (NASDAQ:GTHP) acquired 27,778 shares of common stock at $0.18 per share, for a total value of $5,000 on August 29, 2025. The stock, currently trading at $0.28, has shown remarkable momentum with a 191% gain over the past six months. The micro-cap company, valued at $23.24 million, has demonstrated strong market performance despite not being profitable in the last twelve months.
The same day, James also purchased 27,778 warrants, exercisable at $0.25, expiring on August 28, 2029. According to InvestingPro analysis, GTHP is currently trading above its Fair Value, with 10+ additional investment insights available to subscribers. Check out our Most Overvalued Stocks list for more trading opportunities.
In other recent news, Guided Therapeutics , Inc. has completed patient enrollment for its clinical study of the LuViva Advanced Cervical Scan. The study reached approximately 430 patients across four clinics. The company will now focus on analyzing the data, which involves an external review of biopsy samples, processing case report forms, and performing statistical analysis in line with the study protocol. This marks a significant step in the clinical evaluation process, as no additional patients will be enrolled at any of the clinical sites. These recent developments are crucial for the company’s ongoing efforts to advance its medical technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.